Reach Us +44-1235-425476
Right Atrial Size and 30-Day Mortality in Normotensive Patients with Pulmonary Embolism | OMICS International
ISSN: 2161-105X
Journal of Pulmonary & Respiratory Medicine

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Right Atrial Size and 30-Day Mortality in Normotensive Patients with Pulmonary Embolism

José Luís Lobo1, Vanessa Zorrilla1, José A Nieto 2, Vicente Gomez3, Ferrán García-Bragado4, Teresa Bueso5, Andrei Braester6, Manuel Monreal7* and Riete investigators8

1Respiratory Department, Hospital Universitario de Alava, Vitoria, Spain

2Department of Internal Medicine, Hospital Virgen de La Luz, Cuenca, Spain

3Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain

4Department of Internal Medicine, Hospital de Girona Dr. Josep Trueta, Girona, Spain

5Department of Internal Medicine, Hospital Sant Celoni, Sant Celoni, Spain

6Department of Haematology, Western Galilee Hospital, Nahariya, Israel

7Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

8A full list of RIETE investigators is given in the appendix

*Corresponding Author:
Manuel Monreal
Department of Internal Medicine
Hospital Universitario Germans Trias i Pujol
08916 Badalona (Barcelona), Spain,
Tel: 34-669675313
E-mail: [email protected]

Received date: September 25, 2014; Accepted date: November 17, 2014; Published date: November 21, 2014

Citation: Lobo JL, Zorrilla V, Nieto AJ, Gomez V, García-Bragado F, et al. (2014) Right Atrial Size and 30-Day Mortality in Normotensive Patients with Pulmonary Embolism. J Pulm Respir Med 4:218. doi:10.4172/2161-105X.1000218

Copyright: © 2014 Lobo JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Pulmonary & Respiratory Medicine


Background: The role of right atrial (RA) dilatation for predicting mortality in normotensive patients with pulmonary embolism (PE) has not been thoroughly studied.

Methods: We used the RIETE Registry data to evaluate the prognostic value of RA dilatation (visual estimate) on transthoracic echocardiography (ETT) in patients with acute PE presenting with systolic blood pressure levels ≥90 mm Hg.

Results: As of April 2013, 7,677 normotensive patients with acute PE underwent ETT within the first 48 hours. Of these, 2,268 (29.5%) had RA dilatation. At 30 days, 212 patients (2.76%) died, of whom 59 (0.77%) died of confirmed PE. Patients with RA dilatation had a 6-fold higher rate of fatal PE (1.85% vs. 0.31%; odds ratio [OR]: 5.98; 95% CI: 3.44-10.8) and a 2-fold higher all-cause mortality (4.32% vs. 2.11%; OR: 2.10; 95% CI: 1.59-2.76) compared with those without RA dilatation. On multivariable analysis, RA dilatation independently predicted fatal PE (relative risk [RR]: 3.71; 95% CI: 1.68-8.17), while right ventricle hypokinesis did not (RR: 1.36; 95% CI: 0.66-2.80).

Conclusions: Among normotensive patients with acute PE, RA dilatation on ETT independently predicted fatal PE at 30 days.


Echocardiography; Right atrial dilatation; Pulmonary embolism; Mortality; Prognosis


In patients with pulmonary embolism (PE), early mortality rates range from over 50% in those initially presenting with cardiogenic shock to less than 5% in those with systolic blood pressure (SBP) levels over 90 mm Hg [1-6]. Based on risk profiles, some patients with acute PE may require hospitalization or even immediate recanalization of the occluded pulmonary arteries with thrombolytic therapy or surgery, while others may safely undergo treatment at home and avoid hospital admission [7-10]. One area of controversy focuses on the extension of the indication for thrombolytic therapy to a subgroup of patients who appear stable at presentation but have impending right ventricular failure and a high risk of PE-related death. Thus, a major challenge is the identification of potential candidates for thrombolytic therapy by a simple, rapid, and non-invasive method.

Transthoracic echocardiography (TTE) may detect changes occurring in the right ventricle (RV) anatomy and function as a result of PE-associated acute pressure overload, and some of these abnormalities have been associated with outcome in patients with acute PE [11-13]. However, the complex anatomy of the RV and the subjective nature of routinely obtained standard measurements often limit its usefulness in clinical practice, since reliable and reproducible indices of RV dysfunction are difficult to obtain [13-15]. On the contrary, the right atrium (RA) can be clearly seen in the apical view, and its dimensions easily assessed, thus reducing measurement variability [16,17]. In patients with idiopathic pulmonary hypertension, RA dilatation has been associated with outcome [18], and recent studies in patients with acute PE have correlated the RA size with the severity of PE assessed with scintigraphy or CT-scan [16,19], However, no studies have thoroughly evaluated the relationship between RA dilatation on TTE and outcome in patients with acute PE.

The RIETE (Registro Informatizado de Enfermedad TromboEmbólica) Registry is an ongoing, multicenter, international (Spain, Italy, France, Israel, Germany, Switzerland, Czech Republic, Macedonia, Portugal and Ireland), observational registry of consecutive patients with symptomatic, objectively confirmed, acute venous thromboembolism (VTE). It started in Spain in 2001, and 6 years later the database was translated into English aimed to expand the Registry to other countries. Data from this registry have been used to evaluate outcomes after acute PE, such as the frequency of recurrent VTE, bleeding and mortality, and risk factors for these outcomes [20-23]. In the current study, we used the RIETE database to compare the 30-day mortality of patients with acute PE presenting with SBP levels ≥ 90 mm Hg, according to the presence or absence of RA dilatation on TTE at baseline.

Patients and Methods

Study population

The study population includes all patients with symptomatic acute PE confirmed by objective tests (ventilation/perfusion lung scintigraphy, helical CT-scan or pulmonary angiography) who presented with systolic blood pressure levels ≥ 90 mm Hg and who underwent TTE within the first 48 hours. All patients provided oral consent to their participation in the registry, according to the requirements of the Ethics Committee within each hospital. The therapeutic approach was left to the decision of the attending physician.

The attending physicians ensured that eligible patients were consecutively enrolled. Data were recorded on to a computer-based case report form at each participating hospital and submitted to a centralized coordinating center through a secure website. Encryption of data was used to enhance confidentiality and security. Data quality was regularly monitored and electronically documented to detect inconsistencies or errors, which were resolved by the local coordinators. Data quality was also periodically monitored by contract research organizations, that compared the medical records with the data in the web. A data audit was performed at periodic intervals. Patient identities remain confidential because they were identified by a unique number assigned by the study coordinating center, which was responsible for all data management.

Study design

The major outcome was fatal PE at 30 days. The secondary outcome was all-cause mortality at 30 days. Fatal PE, in the absence of autopsy, was defined as any death appearing within 10 days after PE diagnosis (either the initial event or recurrent PE), in the absence of any alternative cause of death. The causes of death were adjudicated by the attending physicians. In case of doubt, the cause of death was adjudicated by the RIETE Adjudication Committee.

Study variables

The following qualitative TTE parameters were evaluated: RA dilatation (visual estimate), RV hypokinesis (visual estimate) and visualization of thrombus. To measure RA we considered its transverse diameter on the apical four-chamber view. RA dilatation was considered when it was larger than the left atrium. RV hypokinesis was assessed in the apical four-chamber view. In addition, the following quantitative TTE parameters were evaluated in only some patients: RV end-diastolic diameter (on M-mode in the parasternal long-axis view), ratio of right vs. left ventricle end-diastolic diameter (in the apical four- chamber view), tricuspid annular plane systolic excursion (TAPSE), and pulmonary artery pressure (PAP) levels. To obtain TAPSE, the apical four-chamber view was used, and an M-mode cursor was placed through the lateral tricuspid annulus in real time. TAPSE was measured as the total displacement of the tricuspid annulus (centimeters) from end-diastole to end-systole, with values representing the average TAPSE of three to five beats.

The following parameters were also recorded in all patients: baseline characteristics; clinical status including any coexisting or underlying conditions such as chronic heart or lung disease; risk factors for PE; the type and dose of treatment received upon PE diagnosis; and the outcome within the first 30 days.

Treatment and follow-up

Patients were managed according to the clinical practice of each participating hospital (i.e., there was no standardization of treatment). After diagnosis, all patients were followed-up for at least one month, but a longer follow-up was favored, if possible. At each visit, any signs or symptoms suggesting recurrent PE or bleeding complications were noted. Each episode of clinically suspected recurrent PE was investigated by repeat lung scanning, helical-CT scan or pulmonary angiography, as appropriate.

Statistical analysis

The clinical characteristics, treatment strategies and 30-day mortality of patients with or without RA dilatation at baseline were compared. Student’s test and Mann-Whitney tests were used to compare continuous variables. Categorical variables were compared using the Fisher exact test. Kaplan-Meier curves were used to estimate mortality over time, with differences between groups assessed with the log-rank test. Cox proportional hazards regression models were used to test for an independent association between RA dilatation and 30-day mortality. A manual backward stepwise approach was used to develop the multivariate models. Statistical significance was defined as a two- tailed P-value of <0.05 for all analyses. All analyses were completed using the Statistical Package for Social Sciences (SPSS) program (version 15.0 for Windows, SPSS Inc. Chicago, Illinois, USA).


As of April 2013, 7677 patients with acute PE presenting with SBP levels ≥90 mm Hg underwent TTE within the first 48 hours. Of these, 2268 patients (29.5%) had RA dilatation. Patients with RA dilatation were significantly older and more likely had chronic heart failure, chronic lung disease or abnormal creatinine levels than those with no RA dilatation (Table 1). They presented with lower SBP levels, and more likely had hypoxemia and/or electrocardiographic features suggesting acute RV overload (right bundle branch block, S1Q3T3 pattern). Furthermore, patients with RA dilatation more likely had additional TTE findings suggesting right heart overload, such as RV hypokinesis, higher PAP levels, higher RV diameter, or lower TAPSE (Table 1).

  Atrial No atrial p value
Dilatation dilatation
Patients, N 2,268 5,409  
Clinical characteristics
Age (years) 68±16 65±17 <0.001
Gender (males) 1,012 (45%) 2,485 (46%) 0.289
Cancer 390 (17%) 940 (17%) 0.847
Chronic heart failure 368 (16%) 418 (7.7%) <0.001
Chronic lung disease 382 (17%) 684 (13%) <0.001
Physical examination
Heart rate (bpm) 97±21 92±20 <0.001
Systolic blood pressure levels (mm Hg) 127±23 131±23 <0.001
Atrial fibrillation 305 (13%) 352 (6.5%) <0.001
Right bundle branch block 608 (29%) 749 (15%) <0.001
S1Q3T3pattern 624 (30%) 797 (16%) <0.001
Laboratory tests
Creatinine levels >1.2 mg/dL 507 (22%) 845 (16%) <0.001
PO2 levels (mm Hg) (N=5,215) 62±19 68±22 <0.001
Sat O2 levels (%) (N=5,438) 89±7 92±6 <0.001
RA diameter (cm) (N=207) 4.3±1.5 3.3±1.6 <0.001
Visualization of thrombus 105 (4.6%) 67 (1.2%) <0.001
RV hypokinesis 1,185 (52%) 562 (10%) <0.001
PAP levels (mm Hg) (N=4,649) 55±18 39±15 <0.001
RV diameter (cm) (N=1,314) 3.9±1.2 3.0±0.7 <0.001
TAPSE (cm) (N=1,590) 1.8±0.8 2.1±0.9 <0.001

Table 1: Clinical characteristics and diagnostic tests of 7,677 normotensive patients with acute PE, according to the presence or absence of atrial dilatation on the echocardiogram.

Most patients in both subgroups received low-molecular-weight heparin as initial therapy, with no differences between subgroups in mean daily doses, but a higher proportion of patients with RA dilatation received unfractionated heparin (23% vs. 11%) or thrombolytic therapy (3.4% vs. 1.0%) (Table 2). Then, most patients in both subgroups switched to vitamin K antagonists as long-term therapy. In all, 212 patients (2.76%) died at 30 days, of whom 59 (0.77%) died of confirmed PE. One in every two patients dying of PE (27 of 59, 46%), and one in every 5 with all-cause death (44 of 212, 21%) died within the first 5 days after PE diagnosis (Figures 1 and 2). PE was the most common cause of death among patients with or without RA dilatation, accounting for 43% (42 of 98) and 15% (17 of 114) of the deaths, respectively (Table 2).

  Atrial No atrial p value
dilatation dilatation
Patients, N 2,268 5,409  
Initial treatment
Thrombolytics 76 (3.4%) 53 (1.0%) <0.001
LMWH 1,630 (72%) 4,606 (85%) <0.001
Mean LMWH doses (IU/kg/day) 183±41 183±37 0.93
Initial therapy, UFH 510 (23%) 586 (11%) <0.001
Inferior vena cava filter 83 (3.7%) 164 (3.0%) 0.155
Vitamin K antagonists 1,402 (62%) 3,285 (61%) 0.374
LMWH 721 (32%) 1,907 (35%) 0.004
Mean LMWH doses (IU/kg/day) 173±49 169±44 0.048
30-day outcome
Overalldeath 98 (4.32%) 114 (2.11%) <0.001
 Causes of death  
Pulmonary embolism 42 (1.85%) 17 (0.31%) <0.001
Respiratory insufficiency 9 (0.40%) 12 (0.22%) 0.181
Sudden, unexpected 4 (0.18%) 5 (0.09%) 0.327
Bleeding 5 (0.22%) 10 (0.18%) 0.747
Other 30 (1.32%) 66 (1.22%) 0.712
Unknown 8 (0.35%) 4 (0.07%) 0.005

Table 2: Treatment strategies and 30-day mortality.


Figure 1: Cumulative mortality due to pulmonary embolism, according to the presence or absence of right atrial dilatation at baseline.


Figure 2: Cumulative all-cause mortality, according to the presence or absence of right atrial dilatation at baseline.

The 30-day rate of fatal PE in patients with vs. without RA dilatation was: 1.85% (95% CI: 1.36-2.47) vs. 0.31% (95% CI: 0.19- 0.49), respectively (odds ratio [OR]: 5.98; 95% CI: 3.44-10.8). The 30-day all-cause mortality rate was: 4.32% (95% CI: 3.54-5.22) vs. 2.11% (95% CI: 1.75-2.52), respectively (OR: 2.10; 95% CI: 1.59- 2.76). There were no differences between groups for other causes of death (Table 2). On univariable analysis, patients dying of PE more likely had cancer, chronic heart failure or abnormal creatinine levels, and more likely presented with SBP levels <100 mm Hg, tachycardia, tachypnea, atrial fibrillation, hypoxemia, or a right bundle branch block in the electrocardiogram (Table 3). On the TTE exam, patients subsequently dying of PE more likely had RA dilatation, visualization of thrombus, RV hypokinesis, or PAP levels >35 mm Hg (Table 3).

  Fatal PE No fatal PE Dead Alive
Patients, N 59 7,618 212 7,465
Clinical characteristics
Age >80 years 17 (29%) 1,739 (23%) 85 (40%) 1,371 (22%)
Gender (males) 26 (44%) 3,471 (46%) 92 (43%) 3,405 (46%)
Cancer 20 (34%) 1,310 (17%) 97 (46%) 1,233 (17%)
Chronic heart failure 11 (19%)* 775 (10%) 47 (22%) 739 (9.9%)
Chronic lung disease 13 (22%) 1,053 (14%) 40 (19%)* 1,026 (14%)
Physical examination
Heart rate >110 bpm 24 (41%) 1,651 (22%) 69 (33%) 1,606 (22%)
Respiratory rate >30 pm 4 (40%) 319 (12%) 15 (27%) 308 (12%)
SBP levels <100 mm Hg 16 (27%) 809 (11%) 43 (10%) 782 (11%)
Atrial fibrillation 10 (17%)* 647 (8.5%) 37 (18%) 620 (8.3%)
Right bundle branch block 19 (37%) 1,338 (19%) 55 (31%) 1,302 (19%)
S1Q3T3pattern 11 (22%) 1,410 (20%) 34 (19%) 1,387 (20%)
Laboratory tests
Creatinine levels >1.2 mg/dL 20 (34%) 1,332 (18%) 64 (30%) 1,288 (17%)
PO2 levels <60 mm Hg (N=5,215) 28 (70%) 2,226 (43%) 85 (58%) 2,169 (43%)
Sat O2 levels <90% (N=5,438) 29 (76%) 1,981 (37%) 86 (59%) 1,924 (36%)
Right atrial dilatation 42 (71%) 2,226 (29%) 98 (46%) 2,170 (29%)
RA diameter >5.0 cm (N=207) 2 (67%)* 30 (15%) 2 (25%) 30 (15%)
Visualization of thrombus 9 (15%) 163 (2.1%) 11 (5.2%) 161 (2.2%)
Rightventriclehypokinesis 34 (58%) 1713 (23%) 77 (36%) 1670 (22%)
PAP levels >35 mm Hg (N=4,649) 43 (96%) 3262 (71%) 127 (88%) 3178 (71%)
RV diameter >3.0 cm (N=1,314) 6 (86%) 851 (65%) 18 (56%) 839 (65%)
TAPSE <1.6 cm (N=1,590) 3 (60%) 581 (37%) 50 (59%) 564 (36%)

Table 3: Univariable analysis for 30-day mortality.

On multivariable analysis, only hypoxemia (risk ratio [RR]: 4.03; 95% CI: 1.87-8.67) and RA dilatation (RR: 3.71; 95% CI: 1.68-8.17) significantly predicted fatal PE at 30 days while RV hypokinesis did not (RR: 1.36; 95% CI: 0.66-2.80), as shown in Table 4. Subsequently, the influence of chronic lung disease or chronic heart disease on this association was analyzed using an interaction analysis, and RA dilatation persisted as an independent predictor for fatal PE.

  Fatal PE RR (95% CI) P-Value Overall death RR
(95% CI)
Clinical characteristics
Age >80 years     1.92 (1.36-2.69) <0.001
Cancer     3.88 (2.79-5.38) <0.001
Physical examination
Laboratory tests
Sat O2 levels <90% 4.03 (1.87-8.67) <0.001 2.31 (1.54-3.48) <0.001
Atrial fibrillation     2.16 (1.43-3.27) <0.001
Right atrial dilatation 3.71 (1.68-8.17) <0.001 1.26 (0.90-1.77) 0.175
Right ventricle hypokinesis 1.36 (0.66-2.80) 0.407 1.34 (0.95-1.91) 0.099

Table 4: Multivariable analysis for 30-day mortality.

Then, we compared the inter-individual variability in the measurements of RA and RV in one centre (JLL). The intra-class coefficient of correlation was 0.806 (95% CI: 0.717-0.868), and in only 16% of patients (14 of 88) there was some disagreement for the dilatation of RA (kappa: 0.637). On the contrary, the disagreement for RV dilatation (defined as RVEDD >3.0 cm) appeared in 35% of patients (32 of 92) (kappa: 0.377).

Finally, all RIETE members were recently asked to quantitatively measure the size of RA diameter. It was obtained in 207 patients, and was >5 cm in 32 (15%). Of 3 patients (1.45%) who subsequently died of PE, 2 had a diameter >5 cm and one had ≤5 cm. The hazard ratio of dying of PE in patients with RA diameter >5 cm was 11.1 (95% CI: 1.01-122.7; p=0.049). The area under ROC curve was 0.783 (95% CI: 0.584-0.981).


Normotensive patients with acute PE represent a challenge to the clinician. Although their 30-day mortality rate is rather low (ranging from 2.8% to 6.5% in recent studies), many of them die of PE, mostly during the first week.2-7 In our series, one in every 36 (2.76%) such patients died within the first 30 days, and one in every 4 (59 of 212) died of confirmed PE. We hypothesize that some of these deaths might have been prevented if a more accurate therapy (i.e., thrombolytic therapy or insertion of a vena cava filter) would have been applied. In our series, one in every 3 (29.5%) normotensive patients with PE had RA dilatation, and these patients had a significantly higher risk of dying of PE than those with no RA dilatation. Interestingly, the prognostic value of RA dilatation persisted after multivariate adjustment, while RV hypokinesis did not.

During acute PE, there is an increase in pulmonary vascular resistance due to the anatomical obstruction caused by the emboli, release of vasoconstricting agents and reflex hypoxemia [16,24]. The resulting overload induces anatomic changes in the RV that may be identified by TTE, but estimating the volume of a complex structure like the RV is often challenging, not allowing any geometrical assumptions, and diameters or areas are used as surrogate measures in 2D echocardiography [24]. In fact, visual estimate of RV dilatation was poor in our study (kappa of 0,377). Estimating PAP levels may be also difficult in the absence of tricuspid insufficiency. In fact, one in every 3 patients in our series (3028 of 7677, 39%) did not have estimated PAP levels.

On the contrary, RA visualization is easier, and its dimensions are reliably obtained on an apical 4-chamber view. However, only a few studies have focused on the prognostic role of RA changes in acute PE to date. The RA assists in filling the RV by acting as a reservoir for systemic venous return when the tricuspid valve is closed, acting a passive conduit in early diastole when the tricuspid valve is open, and as an active conduit in late diastole during atrial contraction [25]. Thus, it should not be unexpected that RA dilatation reliably predicted outcome.

TTE assessment of the right heart has been largely qualitative until very recently, primarily because of the above mentioned difficulties to assess RV size because of its unusual shape [26,27]. Hence, there are few quantitative data so far for the assessment of RV size and function in patients with acute PE. Current guidelines for the TTE assessment of the right heart, issued in 2010 by the American Society of Echocardiography [12], recommend a gradual shift to more quantitative approaches for the assessment of RV size and function. However, since RIETE started in 2001, most patients had information only on PAP levels and visual estimates on RV hypokinesis or RA dilatation. Only recently we started to gather information on quantitative TTE measurements, such as the TAPSE (which is now available for over 1500 patients) or RA diameter. In future studies we will be able to compare the prognostic value of these new measurements, but our current data suggest that images adequate for RA size estimation should be obtained in patients undergoing evaluation for acute PE.

Our study has important limitations. First, only one in every 3 patients with acute PE in RIETE underwent TTE, and this might have biased our findings thus selecting those perceived to be at a higher risk for complications. However, we compared the 30-day mortality rate in patients with and without TTE and found that those not undergoing TTE had a slightly higher mortality: 3.3% vs. 2.9%. The higher mortality rate in patients with no echocardiogram may likely be due to the higher proportion of patients with advanced cancer, but this would need further analyses. Second, we cannot rule out that some co- morbidities leading to increased mortality and RA dilatation (such as chronic lung disease, chronic heart failure or atrial fibrillation) might have influenced the association between RA dilatation and fatal PE. However, the negative interaction analysis suggests that its impact was, if any, minor. Third, the absence of quantitative TTE data is another major limitation, though this has been usual until the recent guidelines from the American Society of Echocardiography [27].

Moreover, visual estimate of RA size (by comparison with LA size) is counterbalanced by the reality that this relation is not uniquely determined by RA size. Patients with LA enlargement might result in a normal RA: LA ratio even though RA size was, in absolute terms, abnormally large. This is the reason why we recently added RA diameter as a new variable into the database: it was measured in 207 patients and those with >5 cm diameter had a significantly higher rate of fatal PE. Thus, we think that correlating RA dilatation with outcome in patients with acute PE could serve as an easy non-invasive way of triaging and better treating patients presenting with this condition. Fourth, given the characteristics of RIETE (over 200 hospitals from 12 countries, recruiting patients for 12 years) it was impossible to coordinate the submission of ETT reports to an independent investigator. We had to rely on the local interpretations at contributing centres. Finally, some patients with PE may have died before obtaining TTE, and this may have also biased our results. Strengths of the current analysis include that a large number of patients were enrolled, and that fatal PE and all-cause death are by far the most important outcomes during the treatment of VTE.

In summary, our findings reveal that one in every 3 patients with acute PE and SBP levels ≥90 mm Hg may have RA dilatation, and that these patients have a significantly higher risk to die of PE within the first 30 days. In our study, the prognostic value of RA dilatation was superior to that of RV hypokinesis, a more often used but less reproducible measurement.

Author Contributions

Study concept and design

JL Lobo, JA Nieto and M Monreal.

Acquisition of data

Analysis and interpretation of data; statistical analysis: JL Lobo, V Zorrilla, V Gómez, F García-Bragado, JA Nieto, T Bueso, A Braester, M Monreal.

Drafting of the manuscript

JL Lobo, M Monreal.

Critical revision of the manuscript for important intellectual content

JL Lobo, V Zorrilla, V Gómez, F García-Bragado, JA Nieto, T Bueso, A Braester, M Monreal.

Study supervision

Lobo, Nieto, Monreal.

The corresponding author, Manuel Monreal, had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Coordinator of the RIETE Registry

Dr. Manuel Monreal (Spain)

RIETE Steering Committee Members

Dr. Hervè Decousus (France)

Dr. Paolo Prandoni (Italy)

Dr. Benjamin Brenner (Israel)

RIETE National Coordinators:

Dr. Raquel Barba (Spain)

Dr. Pierpaolo Di Micco (Italy)

Dr. Laurent Bertoletti (France)

Dr. Sebastian Schellong (Germany)

Dr. Inna Tzoran (Israel)

Dr. Abilio Reis (Portugal)

Dr. Marijan Bosevski (R.Macedonia)

Dr. Henri Bounameaux (Switzerland)

Dr. Radovan Malý (Czech Republic)

RIETE Registry Coordinating Center

S & H Medical Science Service


We express our gratitude to Sanofi Spain for supporting this Registry with an unrestricted educational grant. We also express our gratitude to Bayer Pharma AG for supporting this Registry. Bayer Pharma AG’s support was limited to the part of RIETE outside Spain, which accounts for a 17, 94% of the total patients included in the RIETE Registry. We also thank the Registry Coordinating Center, S & H Medical Science Service, for their quality control, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma de Madrid and Statistical Advisor S & H Medical Science Service for the statistical analysis of the data presented in this paper.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 12824
  • [From(publication date):
    December-2014 - Jul 19, 2019]
  • Breakdown by view type
  • HTML page views : 9026
  • PDF downloads : 3798